Carlota Recio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6621917/publications.pdf Version: 2024-02-01



CARLOTA RECIO

#	Article	IF	CITATIONS
1	Activation of the Immune-Metabolic Receptor GPR84 Enhances Inflammation and Phagocytosis in Macrophages. Frontiers in Immunology, 2018, 9, 1419.	2.2	110
2	The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease. Frontiers in Pharmacology, 2016, 7, 526.	1.6	77
3	Targeting HSP90 Ameliorates Nephropathy and Atherosclerosis Through Suppression of NF-κB and STAT Signaling Pathways in Diabetic Mice. Diabetes, 2015, 64, 3600-3613.	0.3	64
4	The Mevalonate Pathway, a Metabolic Target in Cancer Therapy. Frontiers in Oncology, 2021, 11, 626971.	1.3	64
5	Suppressor of Cytokine Signaling 1–Derived Peptide Inhibits Janus Kinase/Signal Transducers and Activators of Transcription Pathway and Improves Inflammation and Atherosclerosis in Diabetic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1953-1960.	1.1	59
6	Nrf2 Activation Provides Atheroprotection in Diabetic Mice Through Concerted Upregulation of Antioxidant, Anti-inflammatory, and Autophagy Mechanisms. Frontiers in Pharmacology, 2018, 9, 819.	1.6	59
7	Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 575-585.	3.0	54
8	Peptide Inhibitor of NF-κB Translocation Ameliorates Experimental Atherosclerosis. American Journal of Pathology, 2013, 182, 1910-1921.	1.9	52
9	Acute exposure to apolipoprotein A1 inhibits macrophage chemotaxis in vitro and monocyte recruitment in vivo. ELife, 2016, 5, .	2.8	50
10	SOCS1-targeted therapy ameliorates renal and vascular oxidative stress in diabetes via STAT1 and PI3K inhibition. Laboratory Investigation, 2018, 98, 1276-1290.	1.7	45
11	Peptide-based inhibition of lκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes. Diabetologia, 2015, 58, 1656-1667.	2.9	40
12	FcÎ ³ Receptor Deficiency Attenuates Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1518-1527.	3.0	37
13	Gene delivery of suppressors of cytokine signaling (SOCS) inhibits inflammation and atherosclerosis development in mice. Basic Research in Cardiology, 2015, 110, 8.	2.5	28
14	A Biased Agonist at Immunometabolic Receptor GPR84 Causes Distinct Functional Effects in Macrophages. ACS Chemical Biology, 2019, 14, 2055-2064.	1.6	27
15	Gene Deficiency in Activating Fcl ³ Receptors Influences the Macrophage Phenotypic Balance and Reduces Atherosclerosis in Mice. PLoS ONE, 2013, 8, e66754.	1.1	25
16	Cannabinoid Receptor 2 Modulates Neutrophil Recruitment in a Murine Model of Endotoxemia. Mediators of Inflammation, 2017, 2017, 1-15.	1.4	24
17	Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology. Oncogene, 2019, 38, 4657-4668.	2.6	24
18	Interplay between HSP90 and Nrf2 pathways in diabetes-associated atherosclerosis. ClÃnica E Investigación En Arteriosclerosis, 2017, 29, 51-59.	0.4	21

CARLOTA RECIO

#	Article	IF	CITATIONS
19	Absence of the Non-Signalling Chemerin Receptor CCRL2 Exacerbates Acute Inflammatory Responses In Vivo. Frontiers in Immunology, 2017, 8, 1621.	2.2	18
20	Characterisation of endogenous Galectin-1 and -9 expression in monocyte and macrophage subsets under resting and inflammatory conditions. Biomedicine and Pharmacotherapy, 2020, 130, 110595.	2.5	17
21	The Role of Metabolite-Sensing G Protein-Coupled Receptors in Inflammation and Metabolic Disease. Antioxidants and Redox Signaling, 2018, 29, 237-256.	2.5	13
22	In Vitro Migration Assays. Methods in Molecular Biology, 2018, 1784, 197-214.	0.4	4
23	JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. Biomedicine and Pharmacotherapy, 2021, 144, 112330.	2.5	4
24	Interplay between HSP90 and Nrf2 pathways in diabetes-associated atherosclerosis. ClÃnica E Investigación En Arteriosclerosis (English Edition), 2017, 29, 51-59.	0.1	0